Pagerduty, Inc.
$1.02B- Market cap
- $1.07B
- Debt
- +$420.61M
- Cash
- −$469.84M
Capital structure 72% equity / 28% debt · EV / Revenue 2.08x · EV / EBITDA 25.43x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: PD stock price at discount vs BMRN $13.63 current versus $69.14 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BMRN's multiple
Implied fair value · at PD's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: PD FY 2026 (ended Jan 31, 2026) · BMRN FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 72% equity / 28% debt · EV / Revenue 2.08x · EV / EBITDA 25.43x
Capital structure 96% equity / 4% debt · EV / Revenue 3.75x · EV / EBITDA 21.37x
BMRN carries the larger enterprise value at $12.08B against $1.02B; PD trades on the lower EV / Revenue multiple (2.08x vs 3.75x); BMRN on the lower EV / EBITDA (21.37x vs 25.43x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
PAGERDUTY, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
BIOMARIN PHARMACEUTICAL INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.66x
0.08x
Net debt / EBITDA
Leverage against operating earnings
-1.22x
-1.43x
Cash and equivalents
Liquid reserves on the balance sheet
$469.84M
$1.31B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Atlassian Corp
PD vs TEAM
Gitlab Inc.
PD vs GTLB
Elastic N.V.
PD vs ESTC
Dynatrace, Inc.
PD vs DT
ServiceNow, Inc.
PD vs NOW
VERTEX PHARMACEUTICALS INC / MA
PD vs VRTX
ALNYLAM PHARMACEUTICALS, INC.
PD vs ALNY
Sarepta Therapeutics, Inc.
PD vs SRPT
REGENXBIO Inc.
PD vs RGNX
IONIS PHARMACEUTICALS INC
PD vs IONS
PTC THERAPEUTICS, INC.
PD vs PTCT
$420.61M
$505.32M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.